Logo

UCB's Bimekizumab Receives NICE Recommendation for the Fast-Track Appraisal to Treat Severe Plaque Psoriasis

Share this

UCB's Bimekizumab Receives NICE Recommendation for the Fast-Track Appraisal to Treat Severe Plaque Psoriasis

Shots:

  • NICE has issued a final appraisal determination (FAD) which recommends UCB’s bimekizumab as a treatment option for adults with severe PsO
  • The recommendation is based on four P-III studies i.e BE VIVID- BE RADIANT (P- IIIb)- BE READY & BE SURE that demonstrated the superior efficacy and safety of bimekizumab in adults with PsO against PBO- ustekinumab- secukinumab and adalimumab
  • The company expects MHRA’s decision for approval in the next few mos. if approved- NICE will give final technology appraisal guidance & bimekizumab will be available in England and Wales. The therapy is also under review in the EU & US

 to   | Ref: NICE | Image: NICE

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions